DefenCath® (taurolidine and heparin) catheter lock solution is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.

In the News

Taurolidine cited as an emerging technology in the treatment of Catheter Related Bloodstream Infections

Read more at Becker’s Hospital Review: Infection Control & Clinical Quality

LOCK-IT-100 Trial named in column on the risk of bloodstream infections for long term care patients undergoing dialysis.

Read more at McKnight’s Long Term Care